BioDlink is seeking to acquire all shares of WuXi XDC it does not already own and to cancel all outstanding share options. As of 16:00 Hong Kong time on March 13, valid acceptances had been received for 359.63 million shares, representing 47% of WuXi XDC’s issued share capital and voting rights. Valid acceptances had also been received for 6.51 million share options, representing 85% of outstanding options. The offer deadline was extended to March 27 after the acceptance condition, which requires BioDlink to reach at least 60% of voting rights, was not met by the initial closing date. Three shareholders have agreed to tender a combined 104.04 million shares by March 17 following the extension.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi XDC Cayman Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260313-12051703), on March 13, 2026, and is solely responsible for the information contained therein.